SYNERGY PHARMACEUTICALS LLC
DelistedCIK 1347613fmd_1EXHMV1CS6MRXC5RYTE5DZD7NXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2018, 38 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 0 | 0 | 0 | 17 |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 0 | 9 |
| Gross profit | – | – | – | – | – | – | – | 0 | 0 | 8 |
| Research and development | – | 4 | 10 | 13 | 29 | 51 | 83 | 78 | 87 | 48 |
| Selling, general and administrative | – | – | – | – | – | 12 | 11 | 22 | 58 | 182 |
| Operating income | – | (8) | (16) | (20) | (38) | (62) | (94) | (100) | (145) | (222) |
| Interest expense | – | – | – | 0 | – | 0 | 3 | 17 | 13 | 5 |
| Other non-operating income (expense) | – | 0 | 1 | 6 | (1) | 0 | (1) | (18) | (53) | (2) |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (8) | (15) | (14) | (39) | (62) | – | – | – | – |
| Net income | (32) | (8) | (15) | – | – | – | – | – | – | – |
| Net income to common shareholders | (32) | (8) | (15) | (14) | (39) | (62) | (96) | (118) | (199) | (224) |